CompletedPhase 3

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

United States15 participantsStarted 2019-02-01

Plain-language summary

This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * FSGS * To receive either a live donor or deceased donor kidney transplant Exclusion Criteria: * Not having FSGS

Rate of Recurrence of FSGS as Seen in Renal Transplant Biopsies Proteinuria

Timeframe: 2 years

Rate of Recurrence of Proteinuria

Timeframe: 2 years

NCT IDNCT02683889

SponsorUniversity of Colorado, Denver

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-06

Results submitted2024-10-07